174 related articles for article (PubMed ID: 32498412)
1. The Importance of Accounting for Parameter Uncertainty in SF-6D Value Sets and Its Impact on Studies that Use the SF-6D to Measure Health Utility.
Kharroubi SA; Beyh Y; Abdul Fattah E; Young T
Int J Environ Res Public Health; 2020 Jun; 17(11):. PubMed ID: 32498412
[TBL] [Abstract][Full Text] [Related]
2. Quantifying Parameter Uncertainty in EQ-5D-3L Value Sets and Its Impact on Studies That Use the EQ-5D-3L to Measure Health Utility: A Bayesian Approach.
Pullenayegum EM; Chan KK; Xie F
Med Decis Making; 2016 Feb; 36(2):223-33. PubMed ID: 26139449
[TBL] [Abstract][Full Text] [Related]
3. Use of Bayesian methods to model the SF-6D health state preference based data.
Kharroubi SA
Health Qual Life Outcomes; 2018 Dec; 16(1):234. PubMed ID: 30563528
[TBL] [Abstract][Full Text] [Related]
4. A comparison of Hong Kong and United Kingdom SF-6D health states valuations using a nonparametric Bayesian method.
Kharroubi SA; Brazier JE; McGhee S
Value Health; 2014 Jun; 17(4):397-405. PubMed ID: 24969000
[TBL] [Abstract][Full Text] [Related]
5. The importance of accounting for the uncertainty around the preference-based health-related quality-of-life measures value sets: a systematic review.
Kharroubi SA; Beyh Y
J Med Econ; 2019 Jul; 22(7):671-683. PubMed ID: 30841768
[TBL] [Abstract][Full Text] [Related]
6. Underestimation of Variance of Predicted Health Utilities Derived from Multiattribute Utility Instruments.
Chan KK; Xie F; Willan AR; Pullenayegum EM
Med Decis Making; 2017 Apr; 37(3):262-272. PubMed ID: 27216582
[TBL] [Abstract][Full Text] [Related]
7. The development of a model for translation of the Neck Disability Index to utility scores for cost-utility analysis in cervical disorders.
Richardson SS; Berven S
Spine J; 2012 Jan; 12(1):55-62. PubMed ID: 22209244
[TBL] [Abstract][Full Text] [Related]
8. Predicting SF-6D from the European Organization for Treatment and Research of Cancer Quality of Life Questionnaire scores in patients with colorectal cancer.
Wong CK; Lam CL; Wan YF; Rowen D
Value Health; 2013; 16(2):373-84. PubMed ID: 23538190
[TBL] [Abstract][Full Text] [Related]
9. Modeling SF-6D Health Utilities: Is Bayesian Approach Appropriate?
Kharroubi SA
Int J Environ Res Public Health; 2021 Aug; 18(16):. PubMed ID: 34444157
[TBL] [Abstract][Full Text] [Related]
10. Unchained melody: revisiting the estimation of SF-6D values.
Craig BM
Eur J Health Econ; 2016 Sep; 17(7):865-73. PubMed ID: 26359242
[TBL] [Abstract][Full Text] [Related]
11. A view from the bridge: agreement between the SF-6D utility algorithm and the Health Utilities Index.
O'Brien BJ; Spath M; Blackhouse G; Severens JL; Dorian P; Brazier J
Health Econ; 2003 Nov; 12(11):975-81. PubMed ID: 14601159
[TBL] [Abstract][Full Text] [Related]
12. Valuation of preference-based measures: can existing preference data be used to generate better estimates?
Kharroubi SA
Health Qual Life Outcomes; 2018 Jun; 16(1):116. PubMed ID: 29866108
[TBL] [Abstract][Full Text] [Related]
13. SF-6D population norms for the Hong Kong Chinese general population.
Wong CKH; Mulhern B; Cheng GHL; Lam CLK
Qual Life Res; 2018 Sep; 27(9):2349-2359. PubMed ID: 29797176
[TBL] [Abstract][Full Text] [Related]
14. Discordance in Utility Measurement in Persons with Neurological Conditions: A Comparison of the SF-6D and the HUI3.
Abel H; Kephart G; Packer T; Warner G
Value Health; 2017 Sep; 20(8):1157-1165. PubMed ID: 28964449
[TBL] [Abstract][Full Text] [Related]
15. Modelling SF-6D health state preference data using a nonparametric Bayesian method.
Kharroubi SA; Brazier JE; Roberts J; O'Hagan A
J Health Econ; 2007 May; 26(3):597-612. PubMed ID: 17069909
[TBL] [Abstract][Full Text] [Related]
16. Mapping the Functional Assessment of Cancer Therapy-general or -Colorectal to SF-6D in Chinese patients with colorectal neoplasm.
Wong CK; Lam CL; Rowen D; McGhee SM; Ma KP; Law WL; Poon JT; Chan P; Kwong DL; Tsang J
Value Health; 2012 May; 15(3):495-503. PubMed ID: 22583460
[TBL] [Abstract][Full Text] [Related]
17. EQ-5D-5L and SF-6D Utility Measures in Symptomatic benign Thyroid Nodules: Acceptability and Psychometric Evaluation.
Wong CKH; Lang BHH; Yu HMS; Lam CLK
Patient; 2017 Aug; 10(4):447-454. PubMed ID: 28224296
[TBL] [Abstract][Full Text] [Related]
18. Obtaining SF-6D utilities from FACT-H&N in thyroid carcinoma patients: development and results from a mapping study.
Yang Q; Huang D; Jiang L; Tang Y; Zeng D
Front Endocrinol (Lausanne); 2023; 14():1160882. PubMed ID: 37664851
[TBL] [Abstract][Full Text] [Related]
19. Estimating the SF-6D value set for a population-based sample of Brazilians.
Cruz LN; Camey SA; Hoffmann JF; Rowen D; Brazier JE; Fleck MP; Polanczyk CA
Value Health; 2011; 14(5 Suppl 1):S108-14. PubMed ID: 21839880
[TBL] [Abstract][Full Text] [Related]
20. Use of Bayesian Markov chain Monte Carlo methods to estimate EQ-5D utility scores from EORTC QLQ data in myeloma for use in cost-effectiveness analysis.
Kharroubi SA; Edlin R; Meads D; Browne C; Brown J; McCabe C
Med Decis Making; 2015 Apr; 35(3):351-60. PubMed ID: 25784746
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
